vs
Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and NATIONAL RESEARCH CORP (NRC). Click either name above to swap in a different company.
NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $31.1M, roughly 1.1× LIFECORE BIOMEDICAL, INC. \DE\). NATIONAL RESEARCH CORP runs the higher net margin — 5.1% vs -32.1%, a 37.2% gap on every dollar of revenue. On growth, LIFECORE BIOMEDICAL, INC. \DE\ posted the faster year-over-year revenue change (-4.5% vs -4.6%). NATIONAL RESEARCH CORP produced more free cash flow last quarter ($6.1M vs $25.0K). Over the past eight quarters, LIFECORE BIOMEDICAL, INC. \DE\'s revenue compounded faster (-0.1% CAGR vs -0.2%).
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
LFCR vs NRC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.1M | $35.2M |
| Net Profit | $-10.0M | $1.8M |
| Gross Margin | 25.0% | — |
| Operating Margin | -9.9% | 13.3% |
| Net Margin | -32.1% | 5.1% |
| Revenue YoY | -4.5% | -4.6% |
| Net Profit YoY | -52.0% | -72.6% |
| EPS (diluted) | $-0.29 | $49.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $35.2M | ||
| Q3 25 | $31.1M | $34.6M | ||
| Q2 25 | — | $34.0M | ||
| Q1 25 | $35.2M | $33.6M | ||
| Q4 24 | $32.6M | $36.9M | ||
| Q3 24 | $24.7M | $35.8M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | $35.7M | $35.3M |
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-10.0M | $4.1M | ||
| Q2 25 | — | $-106.0K | ||
| Q1 25 | $-14.8M | $5.8M | ||
| Q4 24 | $-6.6M | $6.6M | ||
| Q3 24 | $-16.2M | $5.7M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | $15.6M | $6.4M |
| Q4 25 | — | — | ||
| Q3 25 | 25.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | 13.3% | ||
| Q3 25 | -9.9% | 22.4% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | -25.7% | 25.6% | ||
| Q4 24 | -6.0% | 26.0% | ||
| Q3 24 | -46.9% | 22.3% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | -2.5% | 24.8% |
| Q4 25 | — | 5.1% | ||
| Q3 25 | -32.1% | 11.9% | ||
| Q2 25 | — | -0.3% | ||
| Q1 25 | -42.0% | 17.2% | ||
| Q4 24 | -20.2% | 17.8% | ||
| Q3 24 | -65.7% | 15.9% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | 43.8% | 18.0% |
| Q4 25 | — | $49.58 | ||
| Q3 25 | $-0.29 | $0.18 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | $-0.47 | $0.25 | ||
| Q4 24 | $-0.25 | $0.27 | ||
| Q3 24 | $-0.53 | $0.24 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | $0.42 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.9M | $4.1M |
| Total DebtLower is stronger | $136.0M | — |
| Stockholders' EquityBook value | $-10.5M | $14.0M |
| Total Assets | $235.2M | $134.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.1M | ||
| Q3 25 | $18.9M | $2.2M | ||
| Q2 25 | — | $5.3M | ||
| Q1 25 | $5.4M | $2.5M | ||
| Q4 24 | $9.5M | $4.2M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $485.0K | ||
| Q1 24 | — | $1.7M |
| Q4 25 | — | — | ||
| Q3 25 | $136.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $106.3M | $48.7M | ||
| Q2 24 | — | $33.3M | ||
| Q1 24 | $97.1M | $35.2M |
| Q4 25 | — | $14.0M | ||
| Q3 25 | $-10.5M | $14.3M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | $2.2M | $29.7M | ||
| Q4 24 | $15.4M | $31.3M | ||
| Q3 24 | $-3.9M | $34.6M | ||
| Q2 24 | — | $40.2M | ||
| Q1 24 | $17.7M | $36.9M |
| Q4 25 | — | $134.9M | ||
| Q3 25 | $235.2M | $135.7M | ||
| Q2 25 | — | $141.4M | ||
| Q1 25 | $237.7M | $135.2M | ||
| Q4 24 | $255.4M | $132.5M | ||
| Q3 24 | $246.8M | $131.8M | ||
| Q2 24 | — | $119.1M | ||
| Q1 24 | $246.2M | $120.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | 5.49× | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $7.2M |
| Free Cash FlowOCF − Capex | $25.0K | $6.1M |
| FCF MarginFCF / Revenue | 0.1% | 17.2% |
| Capex IntensityCapex / Revenue | 5.6% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 3.99× |
| TTM Free Cash FlowTrailing 4 quarters | $-16.8M | $15.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.2M | ||
| Q3 25 | $1.8M | $13.8M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | $1.2M | $6.6M | ||
| Q4 24 | $-6.1M | $6.4M | ||
| Q3 24 | $-613.0K | $9.4M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | $-1.4M | $12.0M |
| Q4 25 | — | $6.1M | ||
| Q3 25 | $25.0K | $10.2M | ||
| Q2 25 | — | $-4.1M | ||
| Q1 25 | $-4.3M | $3.7M | ||
| Q4 24 | $-8.6M | $1.9M | ||
| Q3 24 | $-4.0M | $7.8M | ||
| Q2 24 | — | $1.5M | ||
| Q1 24 | $-7.8M | $7.9M |
| Q4 25 | — | 17.2% | ||
| Q3 25 | 0.1% | 29.4% | ||
| Q2 25 | — | -12.2% | ||
| Q1 25 | -12.1% | 10.9% | ||
| Q4 24 | -26.3% | 5.2% | ||
| Q3 24 | -16.3% | 21.8% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | -21.8% | 22.4% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 5.6% | 10.4% | ||
| Q2 25 | — | 8.8% | ||
| Q1 25 | 15.5% | 8.9% | ||
| Q4 24 | 7.5% | 12.0% | ||
| Q3 24 | 13.9% | 4.5% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | 17.8% | 11.7% |
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | -0.09× | 1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
NRC
Segment breakdown not available.
